NCT05360758View on ClinicalTrials.gov

Ibrutinib Adapted to Response in Patients With CLL

Not yet recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Chronic Lymphocytic Leukemia
Interventions
OTHER

Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia

Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow

All Listed Sponsors
lead

Grupo Argentino de Tratamiento de la Leucemia Aguda

OTHER

NCT05360758 - Ibrutinib Adapted to Response in Patients With CLL | Biotech Hunter | Biotech Hunter